Dongkook Pharmaceutical Moves to Change Name to DK Centellian, "With a Global Focus"

Articles of Incorporation to Be Amended at Nov. 27 Extraordinary Shareholders' Meeting

Dongkook Pharmaceutical said it held a board meeting on October 12 and resolved to pursue a name change to “DK Centellian.”

Dongkook Pharmaceutical, which has continued to focus its business on pharmaceuticals in Korea, said it is pursuing a name change that reflects its commitment and vision to expand into treatment and prevention, as well as the health and beauty sector, and to target global markets.

Dongkook Pharmaceutical's headquarters in Gangnam-gu, Seoul. Dongkook Pharmaceutical

The company added that “DK” represents the 58 years of history the company has built, the scientific trust it has earned, and its corporate roots, which will remain unchanged, while “Centellian” conveys its commitment to creating newer, more future-oriented value based on its accumulated expertise.

A company official said, “We are pursuing a name change to connect with customers around the world through a broader range of businesses in the new era, encompassing not only prevention and treatment but also health and beauty.”

Dongkook Pharmaceutical plans to hold an extraordinary general meeting of shareholders on November 27 and amend part of its articles of incorporation to change its name.

This content was produced with the assistance of AI translation services.